olivLaw · US equity research
Trinity Biotech plc TRIB
In Vitro & In Vivo Diagnostic Substances · SIC 2835 · Vertical: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Trinity Biotech is a biotechnology company developing and selling in vitro diagnostic tests, mainly for diabetes and infectious diseases, and is developing a CGM+ glucose biosensor. The company reported a net loss of 37.4 million USD in 2025, and its high debt and reliance on global HIV program funding make the current period one of transition. For management, liquidity pressure is a central topic.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Trinity Biotech plc (TRIB) stock was 6.43 USD (−2.03% on the day), with market capitalisation 2.4 bn USD, beta 1.46, 52-week range 5.69–38.40 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 41.7
- weak (30–45)
- Bollinger (20, 2)
- 5.77 – 8.29
- in the lower half of the band · %B 0.26 · band width 35.9%
- SMA 50 / 200
- 7.47 / 15.42
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.25 / -0.21
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +11.4% | −1.1% | +12.5 pp | — |
| 3 months | −40.4% | −0.5% | −39.9 pp | — |
| 6 months | −64.3% | +4.4% | −68.7 pp | — |
| Year to date | −72.9% | +12.3% | −85.2 pp | — |
| 1 year | −78.6% | +13.5% | −92.1 pp | −21.1% |
| 3 years | −90.7% | +76.4% | −167.1 pp | −44.4% |
| 5 years | −97.8% | +63.7% | −161.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99.1 m | 97.0 m | 90.4 m | 102.0 m | 81.1 m | 62.5 m | 56.8 m | 61.6 m |
| Revenue YoY | −0.5% | −2.1% | −6.8% | +12.8% | −20.4% | −23.0% | −9.1% | +8.3% |
| Net income | -40.3 m | -22.1 m | -28.9 m | -6.4 m | 875.0 k | -41.0 m | -24.0 m | -31.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | −4,786.7% | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -40.6% | -22.8% | -32.0% | -6.3% | 1.1% | -65.6% | -42.3% | -51.6% |
| Free cash flow | 4.4 m | -299.0 k | 3.3 m | 20.6 m | 11.4 m | -2.0 m | -12.4 m | -4.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2024 · 31 Dec 2024
- Cash
- 5.2 m USD
- Financial debt
- 210.0 k USD
- Net debt
- -5.0 m USD
- Equity
- -35.2 m USD
- Total assets
- 103.3 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.28x
- ROE
- unavailable
- ROA
- -39.1%
- FCF margin
- -7.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 90.4 m | 102.0 m | 81.1 m | 62.5 m | 56.8 m | 61.6 m | SEC (XBRL)· 16 May 2025verified |
| Cost of revenue | 52.3 m | 53.4 m | 47.7 m | 45.3 m | 37.4 m | 40.1 m | SEC (XBRL)· 16 May 2025verified |
| Gross profit | 38.1 m | 48.6 m | 33.5 m | 17.3 m | 19.5 m | 21.4 m | SEC (XBRL)· 16 May 2025verified |
| Research & development | 5.3 m | 5.1 m | 4.5 m | 4.1 m | 4.4 m | 4.5 m | SEC (XBRL)· 16 May 2025verified |
| Operating income | -24.1 m | 82.0 k | 3.9 m | -19.3 m | -27.0 m | -21.2 m | SEC (XBRL)· 16 May 2025verified |
| Depreciation & amortisation | 4.0 k | 40.0 k | 38.0 m | 0 | 0 | 204.0 k | SEC (XBRL)· 16 May 2025verified |
| EBITDA | -24.1 m ≈ | 122.0 k ≈ | 41.9 m ≈ | -19.3 m ≈ | -27.0 m ≈ | -21.0 m ≈ | SEC (XBRL)· 16 May 2025derived |
| Interest expense | 6.6 m | 6.8 m | 7.1 m | 24.7 m | 11.1 m | 9.6 m | SEC (XBRL)· 16 May 2025verified |
| Pre-tax income | -30.0 m | -6.6 m | -1.9 m | -43.8 m | -36.9 m | -30.7 m | SEC (XBRL)· 16 May 2025verified |
| Income tax | -1.0 m | -620.0 k | -74.0 k | -194.0 k | -59.0 k | 486.0 k | SEC (XBRL)· 16 May 2025verified |
| Net income | -28.9 m | -6.4 m | 875.0 k | -41.0 m | -24.0 m | -31.8 m | SEC (XBRL)· 16 May 2025verified |
| Weighted average diluted shares | 101.9 m | 37.7 m | 37.0 m | 79.5 m | — | — | SEC (XBRL)· 16 May 2023verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 15.2 m | 27.3 m | 25.9 m | 6.6 m | 3.7 m | 5.2 m | SEC (XBRL)· 16 May 2025verified |
| Receivables | 21.0 m | 22.7 m | 16.1 m | 15.8 m | 13.9 m | 16.1 m | SEC (XBRL)· 16 May 2025verified |
| Inventories | 32.0 m | 30.2 m | 29.1 m | 22.5 m | 19.9 m | 19.4 m | SEC (XBRL)· 16 May 2025verified |
| Current assets | 71.4 m | 83.3 m | 72.7 m | 46.7 m | 39.0 m | 41.1 m | SEC (XBRL)· 16 May 2025verified |
| Property, plant & equipment, net | 9.3 m | 8.5 m | 5.9 m | 5.7 m | 1.9 m | 4.6 m | SEC (XBRL)· 16 May 2025verified |
| Total assets | 131.1 m | 130.4 m | 118.9 m | 92.1 m | 59.4 m | 103.3 m | SEC (XBRL)· 16 May 2025verified |
| Accounts payable | 7.8 m | 7.1 m | 6.8 m | 6.2 m | 3.9 m | 6.8 m | SEC (XBRL)· 16 May 2025verified |
| Long-term debt | 82.0 m | 82.7 m | 83.3 m | 210.0 k | 210.0 k | 210.0 k | SEC (XBRL)· 16 May 2025verified |
| Current liabilities | 19.4 m | 27.1 m | 100.5 m | 17.3 m | 15.0 m | 32.1 m | SEC (XBRL)· 16 May 2025verified |
| Total liabilities | 126.4 m | 132.6 m | 119.2 m | 94.3 m | 83.4 m | 138.5 m | SEC (XBRL)· 16 May 2025verified |
| Equity | 4.7 m | -2.2 m | -319.0 k | -2.2 m | -23.9 m | -35.2 m | SEC (XBRL)· 16 May 2025verified |
| Shares outstanding at year end | 83.6 m | 83.6 m | 83.6 m | 152.4 m | 153.3 m | 359.2 m | SEC (XBRL)· 16 May 2025verified |
Cash flow · USD
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 5.4 m | 23.8 m | 13.2 m | -921.0 k | -11.6 m | -4.2 m | SEC (XBRL)· 16 May 2025verified |
| Capex | 2.1 m | 3.2 m | 1.8 m | 1.1 m | 803.0 k | 405.0 k | SEC (XBRL)· 16 May 2025verified |
| Free cash flow | 3.3 m ≈ | 20.6 m ≈ | 11.4 m ≈ | -2.0 m ≈ | -12.4 m ≈ | -4.6 m ≈ | SEC (XBRL)· 16 May 2025derived |
| Investing cash flow | -11.9 m | -10.2 m | -8.7 m | -6.0 m | 24.8 m | -23.0 m | SEC (XBRL)· 16 May 2025verified |
| Financing cash flow | -7.5 m | -2.7 m | -6.0 m | -12.3 m | -16.0 m | 28.8 m | SEC (XBRL)· 16 May 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.4 bn USD
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
33% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.11 – 0.16 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)0.11 – 0.16 (Mid 0.13)WACC 9.3% · starting FCFF 3.4 m USD · terminal value share of EV 72%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -51.6% | 47 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -8.8% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -2.2x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 1.3x | 40 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -0.2% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet16/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial47/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
TRINITY BIOTECH PLC (TRIB). Latest full fiscal year: 2024; data up to 2024-12-31.
Figures computed from the financial statements: revenue 61.6 m USD in 2024; YoY growth 8.3%; net margin -51.6%.
The estimated value range is 0.11–0.16 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 0.13 USD, the price of 6.43 USD leaves a potential of -98.0% (value / price − 1) and a margin of safety of -4,868.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Revenue CAGR 3Y: -8.8%
- Interest coverage: -2.2x
- FCF yield: -0.2%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
In Vitro & In Vivo Diagnostic Substances (SIC 2835) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IDXXIdexx Laboratories Inc | 55.0 bn | 47.1 | 68.9% | 25.4% | +10.4% | −7% / +50% |
| LNTHLantheus Holdings, Inc. | 6.6 bn | 24.5 | 22.2% | 17.7% | +0.5% | +72% / +41% |
| NEOGNeogen Corporation | 2.7 bn | — | -2.7% | -6.3% | −2.7% | +108% / −27% |
| TRIBTrinity Biotech PLC | 2.4 bn | — | — | -51.6% | +8.3% | −79% / −91% |
| CLDXCelldex Therapeutics, Inc. | 2.4 bn | — | -43.9% | -190,220.9% | −78.0% | +11% / −1% |
| NTLAIntellia Therapeutics, Inc. | 1.7 bn | — | -6,424.8% | -672.2% | +16.9% | +37% / −58% |
| QDELQuidelortho Corp | 984.6 m | — | -19.3% | -14.2% | −1.9% | −48% / −79% |
| ACHVAchieve Life Sciences, Inc. | 718.3 m | — | -845.0% | — | unavailable | +43% / +21% |
| MYGNMyriad Genetics, Inc. | 575.8 m | — | -32.5% | -14.0% | −1.6% | −21% / −68% |
| TKNOAlpha Teknova, Inc. | 395.7 m | — | -24.2% | -38.4% | +7.4% | +57% / +261% |
| ICCCImmuCell Corporation | 94.2 m | 138.2 | 2.6% | 2.6% | +4.3% | +114% / +128% |
| IMDXInsight Molecular Diagnostics Inc. | 86.7 m | — | — | -2,955.6% | +115.6% | −57% / −30% |
| BMRABiomerica, Inc. | 8.0 m | — | -113.8% | -115.5% | −16.2% | −27% / −77% |
| CDIOCardio Diagnostics Holdings, Inc. | 4.9 m | — | -75.4% | -44,771.8% | −57.5% | −43% / −97% |
| QCLSQ/C Technologies, Inc. | 3.2 m | — | -155.0% | — | −5.3% | −89% / −100% |
| VNRXVolitionRx Limited | 2.8 m | — | — | -1,043.1% | +40.0% | −97% / −99% |
| VRAXVirax Biolabs Group Ltd | 695.1 k | — | -109.6% | -95,739.2% | −96.0% | −88% / −98% |
| NNNNAnbio Biotechnology | — | 25.0 | 27.0% | 74.1% | +5.6% | −84% / unavailable |
1- and 3-year price returns: for TRIB from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Apr 2026; since then the company filed 6-K (05 Oct 2026), 6-K (09 Sept 2026), 6-K (08 Sept 2026), 6-K (28 Aug 2026), 6-K (17 Aug 2026), 6-K (14 Aug 2026).
In brief
Trinity Biotech is a biotechnology company developing and selling in vitro diagnostic tests, mainly for diabetes and infectious diseases, and is developing a CGM+ glucose biosensor. The company reported a net loss of 37.4 million USD in 2025, and its high debt and reliance on global HIV program funding make the current period one of transition. For management, liquidity pressure is a central topic.
SWOT
Strengths
- The company has a broad product base and a distribution network across many countries, including areas with high demand for HIV testing 1.
- The Premier HbA1c platform has recent clinical recognition, which strengthens its competitive position in this segment 1.
- The transformation programme reduced the fixed cost base and moved support functions to lower-cost jurisdictions 1.
Weaknesses
- The company has repeated net losses and negative operating cash flow, which leaves it dependent on external financing 1.
- High indebtedness and financial covenants required waivers and deferrals from its principal lender 1.
- Revenue is sensitive to order timing and external funding, which led to breaches of contractual thresholds 1.
Opportunities
- If the CGM+ platform meets its planned clinical milestones, the company could enter the continuous glucose monitoring market 1.
- A recovery in HIV product demand could again support revenue from existing lines if global funding stabilises 1.
- A data and AI-driven strategy could open new services in metabolic health 1.
Risks
- Liquidity and going concernhigh
Management states that cash resources are sufficient for at least twelve months, but if negative operating cash flow persists, resources could become insufficient 1.
- Debt and conversion into shareshigh
The principal lender may convert part of its debt into ADSs at its discretion, which could significantly dilute existing shareholders 1.
- Covenant breachhigh
The company breached a minimum revenue covenant for the quarter ended December 31, 2025, and the waivers obtained depend on meeting revised conditions 1.
- Dependence on external HIV programmesmedium
Revenue can be affected by the timing of external funding and by exclusion from certain HIV testing algorithms, which could reduce demand 1.
- CGM+ developmentmedium
Clinical trials needed for regulatory approval are expensive, and the success of the platform is not assured 1.
Investment thesis
What would need to be true (bull case)
- If cost reductions and the move of production translate into better margins, the company could reach a more stable operating base 1.
- The IFCC Gold Classification for the Premier Hb9210 could strengthen its competitive position in HbA1c testing 1.
- If the CGM+ platform advances and attracts investors, it could open a revenue line distinct from traditional diagnostics 1.
What would break the thesis
- Repeated net losses and negative operating cash flow suggest continued dependence on external financing 1.
- High debt and the possibility of conversion into shares could dilute existing shareholders and limit financial flexibility 1.
- If demand for HIV products does not stabilise, revenue could remain under pressure in the short term 1.
What to watch
- Covenant compliance and minimum cash balanceQ3 2026
- Results of pivotal clinical trials for CGM+2026
- Maturity of the principal term loan and refinancing arrangementsQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Apr 2026; since then the company filed 6-K (05 Oct 2026), 6-K (09 Sept 2026), 6-K (08 Sept 2026), 6-K (28 Aug 2026), 6-K (17 Aug 2026), 6-K (14 Aug 2026).
The business
Trinity Biotech plc, incorporated in Ireland and listed on Nasdaq under the symbol TRIB, describes itself as a biotechnology company focused on human diagnostics and diabetes management, including wearable biosensors 1. Its products, developed, acquired, manufactured and marketed through subsidiaries, detect autoimmune, infectious and sexually transmitted diseases, liver and intestinal disorders, and markers for diabetes. The company markets several hundred products in approximately 100 countries through its own sales force and a network of international distributors 1. In 2024 it acquired the biosensor assets of Waveform Technologies, on which it is developing a CGM device that remains in development 1.
Segments
Point-of-care and clinical laboratory diagnostics
The company supplies clinical laboratories and the point-of-care segment with rapid tests and instruments, including the Uni-Gold and TrinScreen HIV tests, whose manufacturing has moved to an outsourced offshore model 1. The Premier Hb9210 HbA1c analyser received the IFCC Gold Classification for 2026 in February 2026, which the company says makes it the only HbA1c analyser worldwide with this recognition 1. The range also includes infectious disease tests for syphilis and herpes and clinical chemistry reagents 1.
Autoimmune diagnostics
The Immco line serves the lower-throughput specialty segment of clinical and reference laboratories, mainly in the United States 1. It includes immunofluorescence, ELISA, Western Blot and line immunoassay formats for conditions such as rheumatoid arthritis, lupus and Crohn's disease 1.
CGM biosensors and CGM+ platform
The company is redeveloping a CGM system based on the Waveform technology, with needle-free insertion and a reusable transmitter, which management says could lower production costs and biological waste 1. Project costs for the CGM programme fell compared with the prior year, and pivotal clinical trials are planned for 2026, subject to funding 1.
Market context
According to the company, the global healthcare market is growing because of lifestyle changes and rising incidence of diabetes and autoimmune and infectious diseases, which increases demand for rapid and continuous monitoring tests 1. However, international funding for global health programmes, including HIV initiatives, contracted and was reprioritised in 2025, reducing demand for certain products 1.
Management considers that signs of normalisation at the end of 2025 and in early 2026 could indicate a recovery in demand, although orders remain more variable in timing and payment 1. Tariffs and supply-chain changes are also sources of uncertainty 1.
Trends
- Continuous glucose monitoringmixed
Growing need for continuous monitoring in clinical and consumer settings opens a market for CGM devices, but Trinity has not yet launched a commercial product 1.
- Global health fundingheadwind
Reduced and delayed funding for HIV programmes directly affected sales of legacy lines, and a recovery depends on external decisions the company does not control 1.
- Digital health and artificial intelligencetailwind
Management links the CGM+ strategy to longitudinal physiological data and AI-driven analysis, which could create future revenue if development succeeds 1.
- Tariffs and supply chainsheadwind
Trade changes and tariffs raised costs, and the company moved manufacturing away from its legacy sites to reduce exposure 1.
Competitive position
The diagnostics industry is very competitive, with competition based mainly on product reliability, customer service and price, and with emphasis on automation and new biomarkers 1. The company names several large competitors, including Abbott, Roche, Siemens and Thermo Fisher 1.
In biosensors, competition includes established CGM producers, and Trinity has granted Dexcom a perpetual, non-exclusive licence to some acquired patents 1. For HbA1c products it competes with several laboratory analyser makers 1.
- Abbott Diagnostics
Competitor listed in the company's report in laboratory and point-of-care diagnostics 1.
- DexcomDXCM
Competitor in continuous glucose monitoring and licensee of some Trinity patents 1.
- Roche Diagnostics
Competitor listed in laboratory diagnostics and diabetes testing 1.
- Thermo FisherTMO
Competitor listed in the company's report, active in laboratory diagnostics 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Un trib se opune construirii zidului lui Trump de la granița cu Mexicul. Proiectul ar distruge terenuri sacreMediafax · 28 Aug 2026 · RO
- Un tânăr a renunțat la viața din SUA ca să trăiască într-un trib izolat din pădurea amazoniană și îi place foarte multAntena 3 CNN · 22 Jul 2026 · RO
- Fabuloasele aventuri ale unui colecționar român în Africa neturistică. „Un șef de trib de 100 de ani era rușinat că nu a reușit să taie decât patru capete“Adevărul · 04 Jul 2026 · RO
- SUA trec în revistă evoluția flotei de elicoptere și așteaptă la finalul deceniului noul MV-75 care primește tot nume de trib: Cheyenne II, care va înlocui legendarele Black HawkDefenseRomania.ro · 02 Jul 2026 · RO
- Avertismentul antropologului care a contactat un trib izolat din India: de ce izolarea nu îi mai garantează supraviețuireaAdevărul · 18 May 2026 · RO
The latest news item in our archive is from 28 Aug 2026; the newest SEC filing is from 05 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)05 Oct 2026
- Current report (foreign issuer)09 Sept 2026
- Current report (foreign issuer)08 Sept 2026
- Current report (foreign issuer)28 Aug 2026
- Current report (foreign issuer)17 Aug 2026
- Current report (foreign issuer)14 Aug 2026
- Current report (foreign issuer)22 Jul 2026
- Current report (foreign issuer)22 Jul 2026
- Current report (foreign issuer)02 Jul 2026
- Current report (foreign issuer)30 Jun 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Trinity Biotech plc · 30 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.